The US Food and Drug Administration has issued a public health advisory on Genentech's psoriasis drug Raptiva following four cases and three confirmed deaths from progressive multifocal ...

Genentech withdrew its psoriasis drug Raptiva from the market yesterday, citing the risk of developing progressive multifocal leukoencephalopathy (PML), a rare, often fatal brain infection. The drug ...

Subject: BLA 125075: Raptiva (efalizumab), Genentech Inc., for the proposed treatment of adult patients with moderate to severe plaque psoriasis. Background: The Dermatologic and Ophthalmic Drugs ...

Maidenhead, UK- The UK National Institute for Health and Clinical Excellence (NICE) has brought out guidance to effectively use biological therapies, Enbrel® (etanercept) and Raptiva ...